References
- Centers for Disease Control and Prevention, Department of Health and Human Services. Diabetes data and trends. National Diabetes Fact Sheet 2007. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf. Accessed July 2009
- American Diabetes Association (ADA). Economic costs of diabetes in the US in 2007. Diabetes Care 2008;31:1-20
- Narayan KMV, Boyle JP, Geiss LS, et al. Impact of recent increase in incidence on future diabetes burden. US, 2005–2050. Diabetes Care 2006;29:2114-2116
- American Diabetes Association (ADA). Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917-932
- Caro JJ, Ward AJ, O’Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care 2002;25:476-481
- Trogdon JG, Hylands T. Nationally representative medical costs of diabetes by time since diagnosis. Diabetes Care 2008;31:2307-2311
- American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2007;30(Suppl 1):S1-41
- Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American association of clinical endocrinologists/American college of endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-559
- Ford ES, Li C, Little RR, et al. Trends in A1c concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Diabetes Care 2008;31:102-104
- Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
- The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
- The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
- DCCT/EDIC Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes. J Am Med Assoc 2002;287:2563-2569
- UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
- Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective, observational study. Br Med J 2000;321:405-412
- DCCT Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. J Am Med Assoc 1996;276:1409-1415
- Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM, I: model construction and assumptions. Diabetes Care 1997;20:725-734
- Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM, II: analysis of health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735-744
- Gilmer TP, O’Connor PJ, Manning WG, et al. The cost to health plans of poor glycemic control. Diabetes Care 1997;20:1847-1853
- Wagner EH, Sandhu N, Newton KM, et al. Effect of improved glycemic control on health care costs and utilization. J Am Med Assoc 2001;285:182-189
- Shetty S, Scnik K, Oglesby AK. Relationship of glycemic control to diabetes-related costs for managed care health plan members with type 2 diabetes. J Manag Care Pharm 2005;11:559-564
- Valentine WJ, Palmer AJ, Nicklasson L, et al. Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets. Int J Clin Pract 2006;60:1138-1145